# Clinical outcomes for patients diagnosed with renal cancer and caval thrombus involvement considering surgery

Submission date	Recruitment status	Prospectively registered
09/01/2025	Recruiting	☐ Protocol
Registration date	Overall study status	Statistical analysis plan
07/07/2025	Ongoing	Results
Last Edited	Condition category	Individual participant data
07/07/2025	Cancer	[X] Record updated in last year

### Plain English summary of protocol

Background and study aims

There is considerable uncertainty on how best to treat and select the patients for this high-risk surgery. Surprisingly, the current UK surgical practice of this operation is largely unknown. This lack of knowledge creates a challenge in providing information and optimal care to patients. This study is the UK's first multicentre prospective surgical registry dedicated to improving the care of patients with kidney cancer with caval extension. The researchers will collect detailed information on patients' pre- and post-operative journey, understanding the impact of their surgery and seek information on contemporary surgical practice across the country. In addition, the researchers will collate real-world risks associated with surgery. After 18 months they will hold a national meeting using their results and others in the field using a validated consensus methodology to generate a set of clinical recommendations and create a standard operating procedure for this form of surgery. This will help to provide contemporary informed risks and benefits to patients and places improving patient care from high-risk surgery at the core of the project. Finally, the researchers will generate a patient information leaflet for this form of surgery which they hope can be adopted nationally (e.g. British Association of Urological Surgeons).

### Who can participate?

Any person over the age of 18 referred to a specialist cancer meeting in a hospital that is involved in the study and has a new diagnosis of suspected renal cancer with a tumour clot (caval thrombus) involvement

### What does the study involve?

Patients will undergo routine NHS care and data will be collected from their routine NHS visits.

What are the possible benefits and risks of participating?

There are no additional visits or requirements from the patient above that of routine practice. No changes in patient care result from this study that is observing current practice. No material risk exists to the patient.

Where is the study run from? Imperial College Healthcare NHS Trust (UK)

When is the study starting and how long is it expected to run for? September 2024 to January 2027

Who is funding the study?
The Urology Foundation (TUF) (UK)

Who is the main contact?

Mr Martin Connor, m.connor@imperial.ac.uk

### Contact information

### Type(s)

Public, Principal investigator

#### Contact name

Dr Martin J. Connor

#### **ORCID ID**

https://orcid.org/0000-0003-4033-7508

#### Contact details

Charing Cross Hospital
Department of Surgery and Cancer
London
United Kingdom
W6 8RF
+44 (0)20 3311 1234
m.connor@imperial.ac.uk

### Type(s)

Scientific

#### Contact name

Mr Archie Hughes-Hallett

#### Contact details

Charing Cross Hospital
Imperial College Healthcare NHS Trust
London
United Kingdom
W6 8RF
+44 (0)20 3311 1234
ahughes-hallett@nhs.net

### Additional identifiers

Clinical Trials Information System (CTIS)

### ClinicalTrials.gov (NCT)

Nil known

#### Protocol serial number

No 1057, Imperial College Healthcare NHS Trust

# Study information

#### Scientific Title

Clinical outcomes for CAVAL THROMbus involved Renal Cell Cancer (Imperial Renal 1 – CAVALThromb): a prospective, multicentre registry

#### Acronym

IR1-CAVALThromb

### **Study objectives**

The project is aimed to improve our knowledge and understanding of the optimal surgical treatment for patients with renal cell carcinoma with inferior vena cava involvement

### Ethics approval required

Ethics approval not required

### Ethics approval(s)

As an evaluation of current surgical practice, requirements for formal ethics committee approval were waived by the UK NHS Health Research Authority patients. The registry will be implemented and reported in accordance with the ethical principles of the Declaration of Helsinki. IR1-CAVALThomb will be registered at each side using the current NHS service evaluation forms with associated reference numbers prior to commencing work.

#### Study design

Multicenter registry study

#### Primary study design

Observational

#### Study type(s)

Diagnostic, Quality of life, Treatment, Safety, Efficacy

### Health condition(s) or problem(s) studied

Renal cell carcinoma with inferior vena cava thrombus involvement

#### **Interventions**

IR1-CAVALThromb is a prospective, multicenter, registry study. The researchers plan to invite several centers to the register. They will collect data on patients who undergo radical nephrectomy with caval thrombectomy and non-surgical treatments for their advanced renal cancer.

Broadly the researchers will look at:

- 1. Patient-reported and baseline clinical outcomes
- 2. Intraoperative outcomes
- 3. Adverse events recorded using the Clavien-Dindo classification
- 4. Oncological outcomes

### Intervention Type

Procedure/Surgery

### Primary outcome(s)

Standard operating procedure (SOP) for radical nephrectomy and caval thrombectomy surgery generated using the RAND/University of California at Los Angeles (UCLA) appropriateness method, completed once the last patient recruited has reached 3-month follow-up

### Key secondary outcome(s))

- 1. Morbidity of patients undergoing surgery and those who do not undergo immediate operative management assessed using the Clavien-Dindo Classification and/or the common terminology criteria for adverse events (CTCAEv5.0) at 3-month follow-up
- 2. Patient-reported outcome measures and health-reported quality-of-life measured using:
- 2.1. Clinical frailty score at baseline and 3-month follow-up
- 2.2. EORTC QLQ-F17 and EQ-5D-5L validated questionnaire at baseline and 3-month follow-up
- 3. Surgical complications assessed using the Clavien-Dindo Classification of patients at 3 months follow-up
- 4. Key recommendations for optimal patient care and objectives for further research developed using the RAND/University of California at Los Angeles (UCLA) appropriateness method, completed once the last patient recruited has reached 3-month follow-up

### Completion date

20/01/2027

# **Eligibility**

### Key inclusion criteria

Any person over the age of 18 years referred to a supra-regional MDT following a new diagnosis of suspected caval thrombus involved renal cancer

### Participant type(s)

Patient

### Healthy volunteers allowed

No

### Age group

Adult

#### Lower age limit

18 years

#### Sex

### Key exclusion criteria

- 1. Age under 18 years old
- 2. Patients who are found to have no evidence of caval thrombus on dedicated tertiary imaging

### Date of first enrolment

20/01/2025

### Date of final enrolment

20/01/2027

### Locations

#### Countries of recruitment

**United Kingdom** 

England

### Study participating centre Charing Cross Hospital

Citating Cross Hospita

Fulham Palace Road London United Kingdom W6 8RF

## Study participating centre

The Royal Marsden Hospital (london)

Fulham Road London United Kingdom SW3 6JJ

### Study participating centre

Royal Free London NHS Foundation Trust

Royal Free Hospital Pond Street London United Kingdom NW3 2QG

### Study participating centre

### Norfolk and Norwich University Hospital

Colney Lane Colney Norwich United Kingdom NR4 7UY

# Sponsor information

### Organisation

Imperial College Healthcare NHS Trust

#### **ROR**

https://ror.org/056ffv270

# Funder(s)

### Funder type

Charity

#### Funder Name

**Urology Foundation** 

### Alternative Name(s)

TUF

### Funding Body Type

Private sector organisation

### **Funding Body Subtype**

Trusts, charities, foundations (both public and private)

#### Location

United Kingdom

# **Results and Publications**

### Individual participant data (IPD) sharing plan

The datasets generated during and/or analysed during the current study are not expected to be made available due to the small number of patients and the risk of identifiable data

### IPD sharing plan summary

Not expected to be made available

**Study outputs** 

Output type Details Date created Date added Peer reviewed? Patient-facing?

Participant information sheet 11/11/2025 No Yes